Global Alzheimer's Drugs Market 2014-2018

Global Alzheimer's Drugs Market 2014-2018

Category : Healthcare
Published On : June  2014
Pages : 108



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain. AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three. 
TechNavio's analysts forecast the Global Alzheimer’s Disease Drugs market will grow at a CAGR of 2.61 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Alzheimer's Disease Drugs market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat dementia associated with Alzheimer's disease. 
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Alzheimer's Disease Drugs market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, the Global Alzheimer’s Disease Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Alzheimer’s Disease Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• EMEA 
• APAC
Key Vendors
• Eisai Co., Ltd.
• Forest Laboratories Inc.
• Janssen Pharmaceuticals Inc.
• Novartis AG
Other Prominent Vendors
• Adamas Pharmaceuticals Inc.
• Archer Pharmaceuticals Inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• FORUM Pharmaceuticals Inc.
• H. Lundbeck A/S
• Merck & Co., Inc.
• MorphoSys AG
• Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical, Inc.
• Takeda Pharmaceutical Co., Ltd.
• TauRx Pharmaceuticals Ltd.
• Zinfandel Pharmaceuticals Inc.
Key Market Driver
• Increasing Aging Population 
• For a full, detailed list, view our report
Key Market Challenge
• Poor Diagnosis of Alzheimer’s Disease
• For a full, detailed list, view our report
Key Market Trend
• Increasing Incidence, Prevalence, and Mortality of Alzheimer’s Disease
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

06.1 Dementia

06.2 Epidemiology & Forecast (2013-2018)

06.3 Types of Dementia

07. Alzheimer's Disease

07.1 A Global Burden

07.2 Etiology

07.3 Cost of Care

07.4 Alzheimer's Disease & Caregiving

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 Five Forces Analysis

09. Market Segmentation by MOA

09.1.1 AChE Inhibitors

09.1.2 Glutamate Inhibitors

10. Market Assessment of Top Drugs

10.1 Aricept

10.1.1 Sales

10.1.2 Key Regulatory Approvals and Agreements

10.1.3 US Spending by Various Channels 2010-2013

10.2 Exelon

10.2.1 Sales

10.2.2 Key Regulatory Approvals and Agreements

10.2.3 US Spending by Various Channels 2010-2013

10.3 Namenda

10.3.1 Sales

10.3.2 Key Regulatory Approvals and Agreements

10.3.3 US Spending by Various Channels 2010-2013

10.4 Radazyne

10.4.1 Sales

10.4.2 Key Regulatory Approvals and Agreements

11. Competitive Assessment of Top Drugs

12. Focus on Alzheimer's Research

12.1 National Alzheimer’s Project Act

12.2 Clinical Pipeline

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

21.1 Competitive Scenario

21.1.1 Key News

21.2 Market Share Analysis 2013

22. Future Vendors Expected To Tap the Market

23. Key Vendor Analysis

23.1 Eisai Co., Ltd.

23.1.1 Key Facts

23.1.2 Business Overview

23.1.3 Sales by Geography

23.1.4 Revenue Comparison

23.1.5 Sales by Geography

23.1.6 Business Strategy

23.1.7 Key Information

23.1.8 SWOT Analysis

23.1.9 Strengths

23.1.10 Weaknesses

23.1.11 Opportunities

23.1.12 Threats

23.2 Forest Laboratories Inc.

23.2.1 Key Facts

23.2.2 Business Overview

23.2.3 Business/Product Segmentation

23.2.4 Product Segmentation by Revenue 2013

23.2.5 Business/Products Segmentation by Revenue 2012 and 2013

23.2.6 Sales by Geography

23.2.7 Business Strategy

23.2.8 Key Information

23.2.9 SWOT Analysis

23.2.10 Strengths

23.2.11 Weaknesses

23.2.12 Opportunities

23.2.13 Threats

23.3 Janssen Pharmaceuticals Inc.

23.3.1 Key Facts

23.3.2 Business Overview

23.3.3 Product Segmentation

23.3.4 Business Strategy

23.3.5 Key Information

23.3.6 SWOT Analysis

23.3.7 Strengths

23.3.8 Weaknesses

23.3.9 Opportunities

23.3.10 Threats

23.4 Novartis AG

23.4.1 Key Facts

23.4.2 Business Description

23.4.3 Business Segmentation

23.4.4 Revenue by Business Segmentation

23.4.5 Revenue Comparison 2012 and 2013

23.4.6 Sales by Geography

23.4.7 Business Strategy

23.4.8 Key Developments

23.4.9 SWOT Analysis

23.4.10 Strengths

23.4.11 Weaknesses

23.4.12 Opportunities

23.4.13 Threats

24. Other Reports in this Series



List of Exhibits



Exhibit 1: Market Research Methodology

Exhibit 2: Projected Prevalence of Dementia by Regions 2013-2050 (in millions)

Exhibit 3: Projected Prevalence of Dementia by Regions 2013-2018 (in millions)

Exhibit 4: Types of Dementia by Prevalence 2013

Exhibit 5: Alzheimer’s Disease and Other Dementias Burden by Geographical Segmentation (Annually) 2013

Exhibit 6: Costs of Care by Payer for Americans Age 65 and Older with Alzheimer‘s Disease and Other Dementias 2013

Exhibit 7: Distribution of Alzheimer’s Caregivers by Age, 2013

Exhibit 8: Projected Prevalence of dependence in 2030 (in percent)

Exhibit 9: Global Alzheimer's Disease Drugs Market 2013-2018 (US$ billion)

Exhibit 10: Global Alzheimer's Drugs Market Segmentation by MOA

Exhibit 11: Eisai Co. Ltd.'s Aricept Revenue FY1996-FY2013 (US$ million)

Exhibit 12: Eisai Co. Ltd.'s Aricept Geography-wise Revenue FY1996-FY2010 (US$ million)

Exhibit 13: Eisai Co. Ltd.'s Aricept Geography-wise Revenue FY2011-FY2013 (US$ million)

Exhibit 14: Key Event Timeline of Aricept Formulations

Exhibit 15: Timeline for Aricept Formulations in US and Europe

Exhibit 16: US Spending on Aricept by Various Channels 2010-2013

Exhibit 17: Novartis AG's Exelon Revenue 2001-2013 (US$ million)

Exhibit 18: Novartis AG's Exelon Geography-Wise Revenue 2001-2013 (US$ million)

Exhibit 19: Key Event Timeline of Exelon Formulations

Exhibit 20: US Spending on Exelon by Various Channels 2010-2013

Exhibit 21: Forest's Namenda Revenue 2004-2014 (FY ending March 2014) (US$ million)

Exhibit 22: Key Event Timeline of Namenda Formulations

Exhibit 23: US Spending on Namenda by Various Channels 2010-2013

Exhibit 24: Razadyne Revenue 2007-2009 (US$ million)

Exhibit 25: Key Event Timeline of Razadyne

Exhibit 26: Sales of Top 3 Alzheimer’s Drugs FY 2004-2013 (US$ million)

Exhibit 27: Sales of Top 3 Alzheimer’s Drugs 2004-2013 (US$ million)

Exhibit 28: Alzheimer’s Disease Research Projects by NIH Institutes and Centers 2011

Exhibit 29: NIH funded Alzheimer’s Disease Research Projects by CADRO topic 2011

Exhibit 30: Classification of Disease Modifying Pipeline Molecules by MOA

Exhibit 31: Clinical Trials of Alzheimer’s Disease by Phase 2013

Exhibit 32: Clinical Trials of Alzheimer’s Disease by Recruitment Status 2013

Exhibit 33: Promising Late Stage Pipeline Molecules 2013

Exhibit 34: Global Alzheimer's Drugs market by Geographical Segmentation 2013

Exhibit 35: 65+ Global Population 2014-2018 (in million)

Exhibit 36: Global Alzheimer's Drugs Market Share Analysis 2013

Exhibit 37: Eisai Co., Ltd.: Geographical Segmentation of Revenue for 2013 and 2012(US$ billion)

Exhibit 38: Eisai Co., Ltd.: Revenue comparison for the last 3 years (US$ billion)

Exhibit 39: Eisai Co., Ltd.: Sales by Geography for 2013 (US$ billion)

Exhibit 40: Forest Laboratories Inc.: Product Segmentation (by therapeutic areas) 2013

Exhibit 41: Forest Laboratories Inc.: Product Segmentation by Revenue 2013

Exhibit 42: Forest Laboratories Inc.: Product Segmentation by Revenue 2012 and 2013(US$ million)

Exhibit 43: Company Name: Sales by Geography 2013

Exhibit 44: Janssen Pharmaceuticals, Inc.: Product Segmentation 2013

Exhibit 45: Novartis AG: Business Segmentation

Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013

Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)

Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013



Enquiry Before Buy